Compare Ginkgo Bioworks Holdings Inc (DNA) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Microchip Technology Inc. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.3 (market cap $505.73M), while Microchip Technology Inc. trades at $79.85 (market cap $43.99B). The key difference: Microchip Technology Inc. is far larger — about 87× Ginkgo Bioworks Holdings Inc's market cap, and Microchip Technology Inc. pays a 2.25% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | MCHP | |
|---|---|---|
Market Cap | $505.73M | $43.99B |
Sector | Health | Technology |
52-Week High | $16.14 | $102.97 |
52-Week Low | $5.48 | $49.02 |
Enterprise Value | $607.68M | $49.12B |
Dividend Yield | — | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.42, down 3.01% with bearish technical signals. The company reported Q2 2026 revenue of $20M, down 48% year-over-year, while maintaining a high gross margin of 68.04% but significant net losses. Analyst sentiment is mixed with 45% buy ratings amid ongoing business model transition to autonomous laboratory systems and contract research services.
The outlook remains challenging with persistent revenue declines and negative cash flow, though recent earnings beats provide some optimism. Key risks include execution of the business pivot and path to profitability. Wall Street shows cautious optimism with majority buy ratings despite fundamental headwinds.
Microchip Technology (MCHP) trades at $80.11, down 1.57% over the past day, with a bullish technical signal and strong analyst consensus. Recent earnings beats and robust data center revenue growth, including a 98% surge last quarter, highlight operational momentum. The company maintains solid cash flow and a healthy balance sheet, though elevated valuation ratios like a P/E of 119.15 warrant caution.
Outlook remains positive driven by AI and data center demand, with a consensus price target of $104 implying significant upside. Risks include high debt levels and sensitivity to semiconductor cycles. Institutional sentiment is strong with no sell ratings among 44 analysts, supporting a favorable investment case amid broader tech recovery trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
